DARZALEX FASPRO based regimen shows improvement in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

Johnson & Johnson releases new data from two studies highlighting that a DARZALEX FASPRO based quadruplet regimen demonstrated deep and sustained minimal residual disease negativity rates, and improved long-term progression-free survival in patients with newly diagnosed multiple myeloma, regardless of transplant status.

The study shows the addition of DARZALEX FASPRO to bortezomib, lenalidomide and dexamethasone, followed by an investigational maintenance regimen of DARZALEX FASPRO with lenalidomide, led to improved and deepened rates of overall and sustained MRD negativity for at least 24 months, compared to VRd induction and consolidation with R maintenance.

“The data show that D-VRd followed by an investigational D-R maintenance regimen is a highly effective treatment option for transplant-eligible patients with newly diagnosed multiple myeloma,” said Philippe Moreau, M.D., head of the Hematology Department, University Hospital Hôtel-Dieu, Nantes, France and presenting author. “The depth and durability of MRD negativity observed—paired with unprecedented progression-free survival at four years—underscore the long-term benefit the DARZALEX FASPRO-based regimen can offer patients early in their treatment journey.”

---

---

Related Topics and Keywords

daratumumab and hyaluronidase-fihj, DARZALEX FASPRO®, Johnson and Johnson